Tafasitamab-Cxix

Tafasitamab, an anti-CD19 mAb, has demonstrated promising efficacy in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in Western populations, but its use in Chinese patients has not been reported. This case series reports the use of tafasitamab in four Chinese patients with R/R DLBCL. Four patients with R/R DLBCL were treated at the Department of Hematology, Hainan Hospital of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All patients had previously received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. After treatment with tafasitamab and lenalidomide, two patients with primary refractory disease, one achieved a partial response and another had stable disease. One patient who relapsed after autologous stem-cell transplantation received tafasitamab plus lenalidomide and a Bruton tyrosine kinase (BTK) inhibitor and showed remarkable tumor reduction in all sites except for the lymph nodes in the left inguinal region. One patient who relapsed after second-line therapy achieved complete remission with tafasitamab monotherapy. Tafasitamab-based treatment was well-tolerated, with the most common adverse event being neutropenia. Our real-world experience first suggests that tafasitamab-based flexible treatment may be a potential treatment option for Chinese patients with R/R DLBCL, supporting the need for further investigation into its efficacy and safety in Chinese patients, with a particular focus on exploring directions such as combinations with BTK inhibitors.

Keywords: immunofixation; therapeutic monoclonal antibody; assay interference To the Editor, The development of therapeutic monoclonal antibodies has transformed treatment of malignancies and autoimmune diseases. However, the presence of therapeutic monoclonal antibodies in patient specimens can interfere with clinical laboratory tests, including serum protein electrophoresis (SPEP) and immunofixation, potentially leading to misinterpretation of results. We identified a small immunoglobulin G (IgG) kappa clonal band by immunofixation in a serum specimen from a patient who had no history of prior protein electrophoresis testing in our laboratory (Figure 1). Review of the electronic medical record revealed that this patient had a history of kappa monoclonal free light chain multiple myeloma diagnosed seven years prior, and achieved a stringent complete response with treatment including autologous stem cell transplantation and lenalidomide. Serum free light chain testing performed concurrently with immunofixation was consistent with the continued absence of a monoclonal kappa free light chain, with kappa free light chains measured at 0.005 g/L (0.5 mg/dL), lambda free light chains measured at 0.006 g/L (0.6 mg/dL), and a kappa/lambda free light chain ratio of 0.9. However, while receiving maintenance lenalidomide, the patient developed a second hematologic malignancy, characterized by flow cytometry as B lymphoblastic leukemia/lymphoma. At the time of specimen collection, the patient was undergoing treatment of this second malignancy with a regimen that included tafasitamab. Tafasitamab is a humanized IgG kappa therapeutic monoclonal antibody targeting CD19, which is present on the surface of surface of B lymphocytes. The patient had received multiple doses of tafasitamab prior to immunofixation, with the most recent administration being only 4 days prior to the specimen draw. Pharmacokinetic studies described the mean maximum concentration of tafasitamab at steady-state as 0.5 g/L (500 μg/mL) [1], consistent with the size of the observed band in the patient's specimen. Figure 1:The IgG kappa clonal band in the patient's serum comigrates with the IgG kappa therapeutic monoclonal antibody tafasitamab. Serum gel electrophoresis immunofixation for a normal control sample (left), the patient's sample (middle), and the patient's sample adjacent to 0.5 g/L tafasitamab (right). For each gel, serum electrophoresis (E) is shown along with immunofixation for IgG heavy chain (G), IgA heavy chain (A), IgM heavy chain (M), kappa light chain (κ), and lambda light chain (λ). The control sample was applied at a dilution of 1:6 for IgG and 1:3 for the other immunofixation lanes. The patient's samples were applied at a dilution of 1:3 for IgG and undiluted for the other immunofixation lanes. The tafasitamab was applied undiluted in both lanes. We therefore performed immunofixation of tafasitamab (MedChemExpress) diluted to 0.5 g/L and observed an IgG kappa band with identical electrophoretic migration to the band found in the patient's' specimen (Figure 1). This result strongly suggested that the clonal band in the patient's specimen represented interference from tafasitamab and not a new endogenous monoclonal component. Detection of therapeutic monoclonal antibodies such as tafasitamab can mimic monoclonal gammopathies, posing a diagnostic conundrum for clinicians and laboratory professionals. This highlights the importance of correlating laboratory findings with clinical history. Although tafasitamab is a therapy for B cell lymphoma and not multiple myeloma, for which immunofixation monitoring is indicated, patients treated for multiple myeloma with lenalidomide may be at an increased risk of subsequently developing a second hematologic malignancy, including B lineage disease [2], [3], [4]. Increased age is also a risk factor for lymphoma, and as these patients continue to be monitored for recurrence of myeloma by immunofixation, therapeutic monoclonal antibodies such as tafasitamab that are used for the treatment of lymphoma may become more common in tertiary centers that use such novel therapies. In addition to serum protein immunofixation, tafasitamab has also been described to interfere with flow cytometric assessment for residual disease, causing the potential to mimic the presence of residual lymphoma cells, leading to false conclusion of treatment failure [5]. As our case illustrates, obtaining a complete medication history is crucial to avoid misinterpretation and unnecessary additional workup of patients undergoing therapy with monoclonal antibodies. Fortunately, many therapeutic monoclonal antibodies do not achieve serum concentrations high enough to be detected by serum protein immunofixation, although the list of potentially detectable drugs is growing. Awareness of the possibility of this interference and the migration characteristics of therapeutic monoclonal antibodies can help to prevent misdiagnosis. Corresponding author: Susan L. Fink, Department of Laboratory Medicine and Pathology, University of Washington, 1959 NE Pacific St Box 357110, Seattle, WA, 98195, USA, E-mail: sfink@uw.edu Acknowledgments The authors wish to thank the University of Washington Clinical Immunology Laboratory staff, especially Maggie Mayes and Jeanne Kim, for running the immunofixations. Research ethics: Not applicable. Informed consent: Not applicable. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. Use of Large Language Models, AI and Machine Learning Tools: Not applicable. Conflict of interest: The authors state no conflict of interest. Research funding: None declared. Data availability: Not applicable. References 1. Jurczak, W, Zinzani, PL, Gaidano, G, Goy, A, Provencio, M, Nagy, Z, et al.. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol 2018;29:1266–72. https://doi.org/10.1093/annonc/mdy056.Search in Google Scholar PubMed PubMed Central 2. Saleem, K, Franz, J, Klem, ML, Yabes, JG, Boyiadzis, M, Jones, JR, et al.. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol 2022;9:e906–18. https://doi.org/10.1016/s2352-3026-22-00289-7.Search in Google Scholar 3. Musto, P, Anderson, KC, Attal, M, Richardson, PG, Badros, A, Hou, J, et al.. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017;28:228–45. https://doi.org/10.1093/annonc/mdw606.Search in Google Scholar PubMed 4. Poh, C, Keegan, T, Rosenberg, AS. Second primary malignancies in multiple myeloma: a review. Blood Rev 2021;46:100757. https://doi.org/10.1016/j.blre.2020.100757.Search in Google Scholar PubMed PubMed Central 5. Proost, L, Lambrecht, S, Hofmans, M, De Vriendt, C, Speeckaert, M, Bonroy, C, et al.. Flow cytometry interference in patients treated with tafasitamab: unraveling the diagnostic maze. Hemasphere 2024;8:e39. https://doi.org/10.1002/hem3.39.Search in Google Scholar PubMed PubMed Central Received: 2025-08-06Accepted: 2025-09-07Published Online: 2025-09-15© 2025 the author(s), published by De Gruyter, Berlin/BostonThis work is licensed under the Creative Commons Attribution 4.0 International License.